Join Growin Stock Community!

遠東生技6886.TW Overview

TW StockFoods
(No presentation for 6886)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

遠東生技(6886)Overall Performance

遠東生技(6886)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

遠東生技(6886) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

遠東生技(6886)Key Information

遠東生技(6886)Profile

Far East Bio-Tec Co., Ltd. manufactures and sells organic chlorella, spirulina, and dietary supplements. It also offers nutraceuticals/nutritional supplements, immune booster products, antiviral sprays, and pet supplements. The company was founded in 1976 and is based in Taipei, Taiwan.

遠東生技(6886)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.13
PE Ratio (TTM)
16.24
Forward PE
-
PS Ratio (TTM)
2.17
PB Ratio
2.92
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
49.92%
Net Margin
13.35%
Revenue Growth (YoY)
8.26%
Profit Growth (YoY)
5.50%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.13
PE Ratio (TTM)
16.24
Forward PE
-
PS Ratio (TTM)
2.17
PB Ratio
2.92
Price-to-FCF
-
Gross Margin
49.92%
Net Margin
13.35%
Revenue Growth (YoY)
8.26%
Profit Growth (YoY)
5.50%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6886

遠東生技

50.80D

3.54%

(0.04)

  • When is 6886's latest earnings report released?

    The most recent financial report for 遠東生技 (6886) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6886's short-term business performance and financial health. For the latest updates on 6886's earnings releases, visit this page regularly.

  • Where does 6886 fall in the P/E River chart?

    According to historical valuation range analysis, 遠東生技 (6886)'s current price-to-earnings (P/E) ratio is 19.1, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 6886?

    According to the latest financial report, 遠東生技 (6886) reported an Operating Profit of 33.7M with an Operating Margin of 17.93% this period, representing a growth of 28.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6886's revenue growth?

    In the latest financial report, 遠東生技 (6886) announced revenue of 188M, with a Year-Over-Year growth rate of 11.3%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6886 have?

    At the end of the period, 遠東生技 (6886) held Total Cash and Cash Equivalents of 274.02M, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6886 go with three margins increasing?

    In the latest report, 遠東生技 (6886) achieved the “three margins increasing” benchmark, with a gross margin of 53.36%%, operating margin of 17.93%%, and net margin of 13.99%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6886's profit trajectory and future growth potential.

  • Is 6886's EPS continuing to grow?

    According to the past four quarterly reports, 遠東生技 (6886)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.87. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6886?

    遠東生技 (6886)'s Free Cash Flow (FCF) for the period is -8.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 124.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.